Bone Density Conservation Agents
"Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
| Descriptor ID |
D050071
|
| MeSH Number(s) |
D27.505.696.242
|
| Concept/Terms |
Antiresorptive Agents- Antiresorptive Agents
- Bone Resorption Inhibitors
- Inhibitors, Bone Resorption
- Resorption Inhibitors, Bone
- Bone Resorption Inhibitory Agents
- Antiresorptive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Bone Density Conservation Agents".
Below are MeSH descriptors whose meaning is more specific than "Bone Density Conservation Agents".
This graph shows the total number of publications written about "Bone Density Conservation Agents" by people in this website by year, and whether "Bone Density Conservation Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles.
-
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocr Pract. 2022 Oct; 28(10):1078-1085.
-
Best Practice Guidelines for Assessment and Management of Osteoporosis in Adult Patients Undergoing Elective Spinal Reconstruction. Spine (Phila Pa 1976). 2022 Jan 15; 47(2):128-135.
-
Rush Fracture Liaison Service for capturing "missed opportunities" to treat osteoporosis in patients with fragility fractures. Osteoporos Int. 2018 Aug; 29(8):1861-1874.
-
Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice. Osteoarthritis Cartilage. 2017 12; 25(12):2108-2118.
-
Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States. Chest. 2017 Jan; 151(1):23-33.
-
Considerations regarding adherence of anti-osteoporosis therapy. Postgrad Med. 2015 Jan; 127(1):92-8.
-
Pharmacologic augmentation of implant fixation in osteopenic bone. Curr Osteoporos Rep. 2014 Mar; 12(1):55-64.
-
Advances in acetabular osteolysis: biomarkers, imaging, and pharmacologic management. Instr Course Lect. 2014; 63:177-86.
-
Effect of risedronate in a minipig cartilage defect model with allograft. J Orthop Res. 2009 Mar; 27(3):360-5.
-
National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008 Oct-Dec; 11(4):473-7.